GANGLIONEUROBLASTOMA, NODULAR
Clinical trials for GANGLIONEUROBLASTOMA, NODULAR explained in plain language.
Never miss a new study
Get alerted when new GANGLIONEUROBLASTOMA, NODULAR trials appear
Sign up with your email to follow new studies for GANGLIONEUROBLASTOMA, NODULAR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to keep high-risk neuroblastoma from coming back
Disease control OngoingThis study tests whether adding two chemotherapy drugs (irinotecan and temozolomide) to the standard immunotherapy regimen (dinutuximab, GM-CSF, isotretinoin) can safely prevent high-risk neuroblastoma from returning after intensive initial therapy. About 41 children and young ad…
Matched conditions: GANGLIONEUROBLASTOMA, NODULAR
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Could a 4-Hour infusion replace 20 hours for neuroblastoma kids?
Symptom relief OngoingThis study tests if giving the drug dinutuximab over 4 hours or less is safe and practical for children with high-risk neuroblastoma. Currently, standard infusions take 10-20 hours and require a hospital stay. The goal is to see if a shorter infusion can be used in an outpatient …
Matched conditions: GANGLIONEUROBLASTOMA, NODULAR
Phase: PHASE1 • Sponsor: Children's Hospital Los Angeles • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC